Limited partners include drugs maker Pfizer, and healthcare-focused JSR Group and Lonza.

Dynamk Capital, a US-based venture capital firm, has raised $65m for its debut fund from limited partners including drugs maker Pfizer, and healthcare-focused JSR Group and Lonza. The final close for the Dynamk Life Sciences Fund targets investments in the enabling tools, technologies and services for biopharma companies’ discovery, development and manufacturing needs. Daniella Kranjac,…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.